Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 153

1.

Vonoprazan versus proton pump inhibitors for the management of gastroesophageal reflux disease: A protocol for a systematic review with meta-analysis.

Kang H, Kim BJ, Choi G, Kim JG.

Medicine (Baltimore). 2018 Sep;97(39):e12574. doi: 10.1097/MD.0000000000012574. Review.

2.

Future of Helicobacter pylori and its feasibility.

Talebi Bezmin Abadi A, Kusters JG.

Expert Rev Anti Infect Ther. 2018 Oct;16(10):733-735. doi: 10.1080/14787210.2018.1523715. Epub 2018 Sep 17. No abstract available.

PMID:
30211621
3.

Randomized Controlled Trial Comparing the Effects of Vonoprazan Plus Rebamipide and Esomeprazole Plus Rebamipide on Gastric Ulcer Healing Induced by Endoscopic Submucosal Dissection.

Ichida T, Ueyama S, Eto T, Kusano F, Sakai Y.

Intern Med. 2018 Sep 12. doi: 10.2169/internalmedicine.1146-18. [Epub ahead of print]

4.

[Pharmacological characteristics and clinical efficacies of a novel potassium-competitive acid blocker, vonoprazan fumarate].

Matsukawa J, Inatomi N, Nishida H, Tsukimi Y.

Nihon Yakurigaku Zasshi. 2018;152(3):104-110. doi: 10.1254/fpj.152.104. Japanese.

PMID:
30185727
5.

Smoking and Drinking Did Not Increase the Failure of Therapeutic Helicobacter pylori Eradication by Vonoprazan, Clarithromycin, and Amoxicillin.

Takara Y, Endo H, Nakano R, Kawachi K, Hidaka H, Matsunaga T, Tsuruoka N, Sakata Y, Shimoda R, Hara M, Fujimoto K.

Digestion. 2018 Sep 4:1-7. doi: 10.1159/000490889. [Epub ahead of print]

PMID:
30179876
6.

Two cases of white globe appearance in non-cancerous stomach.

Iwamuro M, Tanaka T, Sakae H, Yamasaki Y, Kanzaki H, Kawano S, Kawahara Y, Okada H.

Ecancermedicalscience. 2018 Aug 7;12:856. doi: 10.3332/ecancer.2018.856. eCollection 2018.

7.

Comparative efficacy of various anti-ulcer medications after gastric endoscopic submucosal dissection: a systematic review and network meta-analysis.

Kim EH, Park SW, Nam E, Lee JG, Park CH.

Surg Endosc. 2018 Aug 30. doi: 10.1007/s00464-018-6409-4. [Epub ahead of print]

PMID:
30167955
8.

Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.

Sue S, Shibata W, Sasaki T, Kaneko H, Irie K, Kondo M, Maeda S.

J Gastroenterol Hepatol. 2018 Aug 27. doi: 10.1111/jgh.14456. [Epub ahead of print]

PMID:
30151994
9.

Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies.

Graham DY, Dore MP, Lu H.

Expert Rev Anti Infect Ther. 2018 Sep;16(9):679-687. doi: 10.1080/14787210.2018.1511427. Epub 2018 Aug 23.

PMID:
30102559
10.

Comparison of the early effects of vonoprazan, lansoprazole and famotidine on intragastric pH: a three-way crossover study.

Ohkuma K, Iida H, Inoh Y, Kanoshima K, Ohkubo H, Nonaka T, Fujita K, Kusakabe A, Inamori M, Nakajima A.

J Clin Biochem Nutr. 2018 Jul;63(1):80-83. doi: 10.3164/jcbn.17-128. Epub 2018 May 9.

11.

Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan.

Shinozaki S, Osawa H, Kobayashi Y, Sakamoto H, Hayashi Y, Miura Y, Kawarai Lefor A, Yamamoto H.

Scand J Gastroenterol. 2018 Aug;53(8):897-904. doi: 10.1080/00365521.2018.1486883. Epub 2018 Jul 28.

PMID:
30056768
12.

Pre-treatment with proton pump inhibitors decreases the success of primary Helicobacter pylori eradication using a vonoprazan-based regimen.

Shinozaki S, Osawa H, Sakamoto H, Hayashi Y, Kobayashi Y, Miura Y, Lefor AK, Yamamoto H.

Kaohsiung J Med Sci. 2018 Aug;34(8):456-460. doi: 10.1016/j.kjms.2018.03.009. Epub 2018 Apr 13.

13.

Second-line triple therapy in failures with vonoprazan-based triple therapy for eradication of Helicobacter pylori.

Mori N, Nishiura Y, Suga D, Moritani I, Yamanaka Y, Ooya Y, Inoue H, Takase K, Hioki M, Shiraki K.

Biomed Rep. 2018 Aug;9(2):169-174. doi: 10.3892/br.2018.1111. Epub 2018 Jun 11.

14.

Vonoprazan versus proton-pump inhibitors for gastric endoscopic submucosal dissection-induced ulcers: a systematic review and meta-analysis.

Jaruvongvanich V, Poonsombudlert K, Ungprasert P.

Eur J Gastroenterol Hepatol. 2018 Jul 6. doi: 10.1097/MEG.0000000000001204. [Epub ahead of print]

PMID:
29985791
15.

Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.

Tanabe H, Yoshino K, Ando K, Nomura Y, Ohta K, Satoh K, Ichiishi E, Ishizuka A, Otake T, Kohgo Y, Fujiya M, Okumura T.

Ann Clin Microbiol Antimicrob. 2018 Jun 28;17(1):29. doi: 10.1186/s12941-018-0281-x.

16.

Efficacy of vonoprazan in prevention of bleeding from endoscopic submucosal dissection-induced gastric ulcers: a prospective randomized phase II study.

Hamada K, Uedo N, Tonai Y, Arao M, Suzuki S, Iwatsubo T, Kato M, Shichijo S, Yamasaki Y, Matsuura N, Nakahira H, Kanesaka T, Yamamoto S, Akasaka T, Hanaoka N, Takeuchi Y, Higashino K, Ishihara R, Okada H, Iishi H, Fukui K, Shimokawa T.

J Gastroenterol. 2018 Jun 25. doi: 10.1007/s00535-018-1487-6. [Epub ahead of print]

PMID:
29943163
17.

Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori.

Li M, Oshima T, Horikawa T, Tozawa K, Tomita T, Fukui H, Watari J, Miwa H.

Helicobacter. 2018 Aug;23(4):e12495. doi: 10.1111/hel.12495. Epub 2018 Jun 6. Review.

PMID:
29873436
18.

Pathogenesis of Potassium-Competitive Acid Blocker-Resistant Non-Erosive Reflux Disease.

Kawami N, Hoshino S, Hoshikawa Y, Takenouchi N, Umezawa M, Hanada Y, Kaise M, Iwakiri K.

Digestion. 2018;98(3):194-200. doi: 10.1159/000488530. Epub 2018 Jun 5.

PMID:
29870976
19.

Severity of gastric mucosal atrophy affects the healing speed of post-endoscopic submucosal dissection ulcers.

Otsuka T, Sugimoto M, Ban H, Nakata T, Murata M, Nishida A, Inatomi O, Bamba S, Andoh A.

World J Gastrointest Endosc. 2018 May 16;10(5):83-92. doi: 10.4253/wjge.v10.i5.83.

20.

Response to: Comment on "First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin".

Sue S, Suzuki N, Shibata W, Sasaki T, Yamada H, Kaneko H, Tamura T, Ishii T, Kondo M, Maeda S.

Gastroenterol Res Pract. 2018 Mar 22;2018:8046838. doi: 10.1155/2018/8046838. eCollection 2018. No abstract available.

Supplemental Content

Loading ...
Support Center